Status:
COMPLETED
Effect Of Detrol LA With Behavioral Intervention In Overactive Bladder Subjects Dissatisfied With Recent OAB Medication.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Urinary Incontinence
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
To evaluate the effect of tolterodine ER in conjunction with behavioral intervention on subject satisfaction in OAB subjects who were dissatisfied with their most recent antimuscarinic OAB medication ...
Eligibility Criteria
Inclusion
- Male and female subjects greater than or equal to 18 years of age
- Overactive bladder symptoms for at least 3 months
- Previously treated with antimuscarinic OAB medications
Exclusion
- Participation in any professionally coached sessions (RN, NP, PA or PT) teaching behavioral interventions
Key Trial Info
Start Date :
October 1 2005
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
417 Patients enrolled
Trial Details
Trial ID
NCT00230789
Start Date
October 1 2005
End Date
December 1 2006
Last Update
January 27 2021
Active Locations (51)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Phoenix, Arizona, United States
2
Pfizer Investigational Site
Sun Lakes, Arizona, United States
3
Pfizer Investigational Site
Little Rock, Arkansas, United States
4
Pfizer Investigational Site
Beverly Hills, California, United States